Revolutionizing Combination Selection Processes to Optimize Response Rates, Effectiveness & Safety - ICI-IO Combinations Summit 2019
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
March 19-21, 2019 | Boston
www.ici-io.com
Revolutionizing Combination Selection
Processes to Optimize Response Rates,
Effectiveness & Safety
A Case Study Based Look at IO Combinations in the
Context of the Cancer Immunity Cycle
Expert Speakers Including:
Jonathan Zalevsky Beth Trehu Raphael Clynes
Senior Vice President, Chief Medical Officer Vice President of
Research and Chief Jounce Therapeutics Translational Biology
Scientific Officer Xencor
NEKTAR Therapeutics
Patrick Holder Jochem Gokelmeijer Catherine Sabatos-
Protein Chemistry Associate Director Peyton
Scientist Bristol-Myers Squibb Director
Genentech Novartis
Osama Rahma Mithun Khattar Paul Moore
Assistant Professor Scientist & Immuno- Vice President - Cell
Dana-Farber Cancer Oncology Lead Biology & Immunology
Institute Takeda MacroGenics
Partners:
Tel: +1 617 455 4188 Mail: info@hansonwade.com
Immune Checkpoint Inhibitors @ici_checkpoint
ICI – IO Combinations Summit
March 19-21, 2019 | Boston
Increasing Effectiveness Hear What Previous
Attendees Have To Say
and Safety of IO Great meeting, very
Combinations
informative, great to see what
other companies are working
on in the field of cancer
This industry-led meeting will focus on how checkpoint immunotherapy
combinations can impact every stage of the cancer Genentech
immunity cycle; enhancing patient outcomes.
The unique format of the agenda offers a complete
This conference was of
perspective of the effects of adaptive and innate immune
outstanding value. First
components on combination success. Appreciate insights
class presentations, great
on the latest data on how drug developers are targeting of
opportunity for networking
immune checkpoints, myeloid cells, cytokines, stromal cells,
and perfect logistics
STING and kinase pathways such as Wnt & PI3K. AstraZeneca
Breaking down these case-studies gives the opportunity to Great opportunity for
take un-pick specific preclinical, translational and clinical discussions between large
challenges. Bringing forward new ideas and concepts that pharma, small start ups,
you can build into your combination rationale. Stop taking academia and regulatory
shots in the dark, and start formulating calculated, precise authorities
studies that will yield results and true clinical value.
Merck
An Unparalleled Depth of Insights
1. 2. 3. 4. 5.
Improve your Learn how Nektar Hear how Jounce Take apart the Predict and plan for
combination Therapeutics Therapeutics current approaches future roadblocks
rationale supercharge reverse translated to target to development
with a greater the tumor their ICOS - identification from through our
mechanistic microenvironment containing biological and interactive
understanding to optimize the combination when protein chemistry workshops on
of the cancer effectiveness it didn’t perform perspectives to preclinical
immunity cycle and of checkpoint as expected to find a faster, more development of
how combinations modulators better inform efficient path to IO combinations
work within it through the use of future decision preclinical testing and maximizing
cytokines making with a discussion the anti-tumor
between panelists capability of the
from Genentech, innate immune
Novartis and system
FusionBio
Tel: +1 617 455 4188 Mail: info@hansonwade.com
2
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.com
ICI – IO Combinations Summit
March 19-21, 2019 | Boston
YOUR EXPERT SPEAKERS
John M. Burke Amy-Jo Casbon Raphael Clynes
Co-Founder, President, Immunotherapy & Vice President of
and Chief Executive Oncology Scientist Translational Biology
Officer Amgen Inc. Xencor
Applied Biomath
Viviana Cremasco Jonathan Zalevsky Cedric Dos Santos
Investigator Senior Vice President, Prinicpal Scientist Heme,
Novartis Research and Chief Oncology, Clinical
Scientific Officer Biomarkers & Therapeutic
NEKTAR Therapeutics Areas Lead
Amgen Inc.
Hans Van Eenemann Shanthi Ganesh Christelle Johnson
Executive Vice President Associate Director Senior Field
Antibody Research and Dicerna Applications
Site Head Scientist
Aduro Biotech Personalis
Jochem Gokemeijer Jeremy Graff Patrick Holder
Associate Director Chief Scientific Officer Protein Chemistry
Bristol-Myers Squibb Biothera Scientist
Genentech
Mithun Khattar Paul Moore Bruno Osterwalder
Scientist & Immuno- Vice President - Cell BO Consulting
Oncology Lead Biology & Immunology
Takeda MacroGenics
Mark Paris Weiyi Peng Osama Rahma
Director, Translational Assistant Professor Assistant Professor
Applications Biopharma University of Houston Dana-Farber Cancer
Business Development Institute
Mitra Biotech Inc.
Paul Rennert Catherine Sabatos- Beth Trehu
President and Chief Peyton Chief Medical Officer
Scientific Officer Director Jounce Therapeutics
Aleta Biotherapeutics Novartis
Wim Van Schooten Eva Vanamee Bei Wang
Chief Scientific Officer Co-Founder Staff Scientist
TeneoBio Fusion Bio Regeneron
Mark Yore Sarah McWhirter Mark Poznansky
Manager of Corporate Director - Sting Program Director, Vaccine and
Development Aduro Biotech Immunotherapy Center
Jounce Therapeutics (VIC), Massachusetts
General Hospital (MGH)
& Associate Professor
Harvard Medical School
Tel: +1 617 455 4188 Mail: info@hansonwade.com
3
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.com
ICI – IO Combinations Summit
March 19-21, 2019 | Boston
PRE-CONFERENCE WORKSHOP DAY
MARCH 19, 2019
Pre-Clinical Development Challenges in
Checkpoint Modulators and IO Combinations
9:00am - 12:00pm
The path to clinical success begins in the lab. We have seen a lot of
molecules struggled through clinical phases due to a lack of pre- Mithun Khattar
clinical understanding.
Scientist & Immuno-
This workshop will give you the practical skills and insight to help you
make informed decisions at the preclinical phase, leading you to more
Oncology Lead
robust and reliable results at the trial stage. Through case studies and Takeda
group discussions, this interactive session will dive into the following
areas, which prime your preclinical understanding prior to the main
conference.
Topics that are being covered include:
• A breakdown of the models that are currently available, their
relative translatability and where they can be implemented best
for both ICIs and IO combinations
• An analysis of the key challenges that are being faced at the
preclinical stage and the key developments that will enable us to
overcome them
• Look at how you can build a robust scientific rationale at the
preclinical stage to drive greater success at the clinical phase
Excellent meeting. Great
opportunity for discussions between
large pharma, small start ups,
academia and regulatory authorities
Merck
Tel: +1 617 455 4188 Mail: info@hansonwade.com
4
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.com
ICI – IO Combinations Summit
March 19-21, 2019 | Boston
CONFERENCE DAY ONE
MARCH 20, 2019
8.30 Chair’s Opening Remarks
8.40 Navigating the complex ICI-IO landscape – Recent updates and Future
Mark Yore Challenges
Manager of
• As the number of CPI-IO trials continue to grow at unprecedented rates,
Corporate
Development understanding the complex nature of this landscape is critical for clinical and
Jounce commercial success
Therapeutics • During the presentation I will discuss the landscape as it stands today, how it’s
evolving, and key challenges that face ICI-containing IO-combinations in the future
Paul Rennert
9.10 Establishing a New Set of Biological Goals for Checkpoint Inhibitors
President and Chief and IO Combinations
Scientific Officer • Look at the current standards that are in place for ICIs and IO combinations
Aleta • Set new goals that scientists must strive to achieve in order to set a new standard
Biotherapeutics of care
9.40 Model Aided Drug Invention Case Study: GITR-Mediated T Cell
dynamics in Mouse Tumor Micro Environment
• Model Aided Drug Invention (MADI) is a mechanistic mathematical modeling
approach used to help reduce late stage attrition rates, help accelerate the
development of premier (or best-in-class) therapeutics and identify potential
R&D hurdles
John M. Burke
• In this collaboration, a MADI approach was used to develop and analyze a
Co-Founder,
President, and Chief systems pharmacology model of an anti-GITR (Glucocorticoid-Induced TNFR-
Executive Officer Related protein) agonist antibody to predict Treg and Teff dynamics in the tumor
Applied Biomath microenvironment in two syngeneic mouse models following administration of
anti-GITR agonist antibody
• The model adequately described the time profiles of intratumoral Treg and Teff,
captured Teff immune checkpoint, Treg depletion by ADCP, and Teff proliferation
and differentiation into cytotoxic T lymphocytes (CTLs). The model also provided
a quantitative understanding of the trade-off between maximizing Treg
depletion vs. Teff agonism
10.10 Speed Networking & Morning Refreshments
Broadening Understanding of the Biological Effects of Checkpoint Inhibitors
11.30 Supercharging the Tumor Microenvironment: Lessons from NKTR-214
and Opdivo
• The idea of combining the immune modulating properties of checkpoint inhibitors
Jonathan Zalevsky and the immune stimulating function of engineered cytokines is conceptually
Senior Vice President, powerful
Research and Chief • Cytokine engineering can alternative cytokines to be more powerful medicines,
Scientific Officer while controlling adverse events
NEKTAR • The combination of NKTR-214 with opdivo has demonstrated powerful anti tumor
Therapeutics effects and profoundly alters the tumor microenvironment, increasing effector
T-cell counts, increasing PD-1 expression on tumor T-cells, and converting PD-L1
negative tumors to positive, while maintaining a more tolerable AE profile than
traditional cytokine therapies
12.00 A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug
Discovery and Development
Mark Paris • Mitra Biotech has developed and clinically validated a fully human ex-vivo tumor
Director, Translational platform technology (CANscript™)
Applications • CANscript ™ uses patient material (tumor, autologous ligands and PBMCs) to
Biopharma Business explore the mechanism of action and predict efficacy for clinically-directed
Development compounds in a modality agnostic way using phenotypic readouts
Mitra Biotech Inc. • This talk will explore how we use CANscript to measure the effect of checkpoint
inhibitor monotherapy or combination to deepen our understanding of response
and resistance
Tel: +1 617 455 4188 Mail: info@hansonwade.com
5
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.com
ICI – IO Combinations Summit
March 19-21, 2019 | Boston
12.30 Lessons Learned from a Clinical Trial Targeting ICOS
Beth Trehu • JTX-2011, an ICOS agonist, was evaluated as monotherapy and in combination with
Chief Medical Officer nivolumab in the ICONIC trial
Jounce • Responses and tumor reductions observed with monotherapy and combination were
associated with a mechanism related pharmacodynamic biomarker
Therapeutics • Reverse translational analyses enabled by biomarkers have redirected JTX-2011
clinical development strategy
13.00 Lunch
Discovery Translational
Enhancing Therapy Efficacy Overcoming Resistance & Personalizing
at the Preclinical Level Combination Therapies
14.00 RNAi-mediated Inhibition of β-Catenin Increases 14.00 Targeting the PI3K Pathway to Overcome
Responses to Multiple Immunotherapy Regimens Across Immune Resistance
a Spectrum of Preclinical Tumor Models • Discuss how tumor intrinsic signaling pathways
• A systemically-administered RNAi drug product targeting
β-catenin increases APCs and cytotoxic T-cells in the TME, modulate T cell-mediated antitumor immune responses.
and promotes synergistic efficacy in combination with • Identification of the mechanism by which oncogenic
immunotherapy in multiple preclinical models activation of the PI3K pathway promotes immune
• Identification of a novel mechanism by which Wnt/β- resistance
catenin signaling promotes resistance to immunotherapy • Development of therapeutic strategies to improve the
• Strategies to rationally design RNAi-containing drug
combinations to increase the response rates to checkpoint efficacy of cancer immunotherapy by combining with
blockade and IDO inhibition PI3K inhibition
Shanthi Ganesh, Associate Director – Oncology, Dicerna Weiyi Peng, Assistant Professor, University of Houston
14.30 Delineating Myeloid Cell Subsets and Their Role in 14.30 Challenges and Solutions: Enabling Multidimensional
Response to Cancer Immunotherapy Tumor Immunogenomics for advancing biomarker discovery
• Myeloid cell subsets associated with immune suppression • Insight into the complex and dynamic interactions
between the tumor and immune cells of the
and immune activation in cancer microenvironment is essential for cancer
• Combination therapies reveal new insights into the pro- immunotherapy biomarker discovery
and anti-tumor contribution of myeloid cells in cancer • Purpose built for precision oncology, the ImmunoID
• Emerging novel strategies for targeting myeloid cells to NeXT Platform investigates key areas of tumor biology;
from elucidating mechanisms of tumor escape and
enhance cancer immunotherapy detecting neoantigens, to characterizing the immune
Amy-Jo Casbon, Scientist – Oncology Research, Amgen repertoire and identifying novel biomarker signatures
• We’ll discuss the current challenges facing investigators
in immuno-oncology translational research including
maximizing data generation from a single sample and
the analysis of complex data
Christelle Johnson, PhD, Senior Field Applications
Scientist, Personalis
15.00 Bispecific and Biparatopic Human Heavy Chain 15.00 BiTE® in Hematologic Malignancies: a Road to a Cure?
Antibodies in Immune Oncology • Review Blincyto® Biomarker data for R/R B-ALL patients
• Discuss different formats of T cell engaging bispecific with an emphasis on predictive and/or prognostic
biomarkers, pharmacodynamic, mechanism of action
antibodies and drug resistance mechanisms post treatment.
• Explore biparatopic heavy chain antibodies against CD38 • Review biomarkers data for other Hem/Onc BiTE®
Wim Van Schooten, Chief Scientific Officer, TeneoBio molecules currently in Phase 1
Cedric Dos Santos, Principal Scientist - Heme, Oncology,
Clinical Biomarkers & Therapeutic Areas Lead, Amgen
15.30 Afternoon Refreshments
Stages 1 – 3: Improving Cancer Antigen Presentation,Driving Stronger Priming and Immune Activation
16.00 STING Pathway Activation Enhances Checkpoint Blockade to Elicit an
Anti-Tumor CD8+ T Cell Response in Preclinical Models
Sarah McWhirter • Describe the rationale for targeting STING within the tumor microenvironment and the
Director - Sting
mechanism of optimal STING-induced anti-tumor CD8+ T cell immunity
Program
Aduro Biotech • Highlight how STING activation enhances the therapeutic effect of checkpoint inhibition
• Explore the immune correlates associated with the combination of STING agonist-
based immunotherapy and checkpoint inhibition
16.30 T Cell Dysfunction and Combination Immunotherapy
• Single-cell analysis of tumor-infiltrating lymphocytes to probe the mechanisms for
Bei Wang combination immunotherapy
Staff Scientist
• PD1/GITR combination immunotherapy led to a synergistic increase in tumor
Regeneron
antigen–specific memory precursor effector T cells dependent on availability of the
CD226 costimulatory pathway
17.00 Chair’s Closing Remarks
Tel: +1 617 455 4188 Mail: info@hansonwade.com
6
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.comICI – IO Combinations Summit
March 19-21, 2019 | Boston
CONFERENCE DAY TWO
MARCH 21, 2019
8.30 Chair’s Opening Remarks
8.40 Re-Training Innate Immunity: Combining the Novel Beta Glucan, Imprime
PGG, with Checkpoint Inhibitors to Drive a Robust, Coordinated Anti-
Cancer Immune Response
Jeremy Graff
Chief Scientific • Imprime PGG binds directly to cells of the innate immune system driving innate
Officer immune cell-mediated tumor killing, re-orienting macrophage polarization and
Biothera enhancing antigen presentation capacity
• Imprime PGG thereby stimulates T cell-mediated immunity
• Imprime PGG mechanistically complements immune checkpoint inhibitor therapy to
trigger a robust anti-cancer immune response
9.10 T Cell Engagers, Checkpoints and Cytokines to Broaden Immune
Responses to Cancer
• IO therapy is limited by poor immune recognition, multiple checkpoints and
insufficient T cell infiltration
• Xencor’s pipeline is focused on overcoming these obstacles to broaden the reach of
IO therapy
Raphael Clynes
• CD3 bispecifics overcomes limited immune recognition by directly activating T cells
Vice President of
Translational Biology by targeting common hematologic and solid tumor specific targets (CD20, CD123,
Xencor SSTR2). Clinical trials and next gen approaches will be discussed
• Bispecific checkpoints clinical trials have been initiated at Xencor (DUET studies)
targeting PD1, CTLA4, ICOS and LAG3. Rationale, preclinical antitumor activity and
clinical plans/updates will be discussed
• Rationally designed T cell cytokines (IL-15 and others) with T cell targeting and long
acting pharmacodynamic preclinical activity will be discussed that potently enhance
intratumoral T cell infiltration
Patrick Holder
Protein Chemistry
Scientist 9.40 Panel Discussion: Mind the Gap - Considering New Targets from Biological
Genentech Rationale to Therapeutic Protein Delivery
• Hear the perspectives from both biological and protein chemistry sides of the
Catherine
Sabatos-Peyton discussion
Director • Hone in on the key areas where each function can support one another in their
Amgen shared goal of accelerating more clinical relevant IO drugs
• Look at the future targets for ICIs and IO combination therapies and assess their
Eva Vanamee true value
Co-Founder
FusionBio
10.30 Morning Refreshments
Discovery Translational
Clinical Biomarkers,
Preclinical Testing and Tumor Modelling
Immunogenicity and Toxicity
11.00 Pre-Clinical Modeling of Immune Responses to 11.00 Understanding Immune-Related Toxicities in the
Cancer: From Bench-Side to Clinical Outcomes Era of Combination Immunotherapies
• Translatability of pre-clinical murine models in immuno- • Patterns of immune-related toxicities
oncology. • Factors that determine toxicities
• Pre-clinical models for investigating combination • Comprehensive program to manage and prevent
therapies. immune-toxicities
• Fundamental differences in the immune system and Osama Rahma, Assistant Professor, Dana-Farber
tumor microenvironments of mice and humans
Mithun Khattar, Scientist & Immuno-Oncology Lead,
Takeda
Tel: +1 617 455 4188 Mail: info@hansonwade.com
7
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.comICI – IO Combinations Summit
March 19-21, 2019 | Boston
11.30 Stromal-Imposed Immunosuppresion in the Era of 11.30 Immunogenicity of I-O Therapeutics: The Good
Checkpoint Blockade and The Bad
• Mesenchymal stromal cells impinge on anti-tumor • I-O therapeutic depended on manipulating immune
immunity checkpoints, one consequence of this is an a
• We still lack a full understanding of the cellular and decreased tolerance including the therapeutic
molecular mechanisms by which stromal-imposed • Is it possible that the MOA of I-O
immunosuppression is exerted therapeutics contribute to immunogenicity to these
• We have identified a discrete population of FAP+ stromal therapeutics
cells in immune-excluded breast cancers with potent • Are I-O combination therapies increasing
immunomodulatory potentia immunogenicity and are there strategies to screen for
Viviana Cremasco, Investigator, Novartis this preclinical
• Strategies to mitigate immunogenicity to I-O
therapeutics
Jochem Gokemeijer, Associate Director, Bristol-Myers
Squibb
12.00 Panel Discussion: Reviewing the Future Challenges 12.00 Panel Discussion: What Are the Solutions to The
in Tumor Modeling for IO Combinations These Immunogenicity Challenges
• Review the current models and preclinical tools that are • Consider a framework by which the effects of specific
available and assess their true value in getting the results IO combos can be predicted, based on what was learnt
that predicate clinical successes and failures in the talks prior
• Identify the weak spots in current development strategies • Discuss trends that were seen between the previous
and discuss how these can be fixed presentations to solve their respective challenges
Mithun Khattar, Scientist & Immuno-Oncology Lead, • Look at combining the capabilities of pharma and
Takeda academia to solve these problems
Viviana Cremasco, Investigator, Novartis Osama Rahma, Assistant Professor, Dana-Farber
Jochem Gokemeier, Associate Director, Bristol-Myers
Squibb
12.45 Lunch
Mark Poznansky
Director, Vaccine
13.45 Development of novel combination immunotherapies for ovarian cancer
and Immunotherapy
Center (VIC), and mesothelioma
Massachusetts • Description of novel products developed at VIC and their preclinical development
General Hospital • Description of novel computational approaches to guide and predict
(MGH) & Associate immunotherapeutic targeting and responsiveness
Professor • Description of path to first in human studies for novel combinations
Harvard Medical
School
Stages 4 – 7: Trafficking and Infiltration of Immune Cells,
Improving the Effectiveness Cell Destruction Mechanisms
Hans Van Eenemann 14.15 Targeting the Innate CD47-SIRPα Checkpoint Using Pan-Allele SIRPα
Executive Vice Blocking Antibodies
President Antibody
Research and Site • Unique pan-allele SIRPα blocking antibody
Head • SIRPα blocking differentiates from CD47 targeting
Aduro Biotech • SIRPα blocking enhances PD-1/PDL1 blocking in vivo
14.45 PD-1-Based Bispecific Antibody Therapies
Paul Moore • Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific
Vice President format is of paramount importance in the preclinical and clinical development of any
Macrogenics bispecific antibody.
• The selection of the right bioanalytical tools is a key consideration of this process
15.15 Chair’s Closing Remarks
Tel: +1 617 455 4188 Mail: info@hansonwade.com
8
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.comICI – IO Combinations Summit
March 19-21, 2019 | Boston
PARTNER
Expertise Partner Expertise Partner
Mitra Biotech is a global leader in Applied BioMath uses
advancing personalized cancer mathematical modeling
treatment and empowering and simulation to provide
drug development & discovery. quantitative and predictive
Our phenotypic CANscript platform delivers powerful guidance to biotechnology and pharmaceutical
insight for our biopharma partners. Because CANscript companies to help accelerate and de-risk drug research
conserves the native tumor microenvironment and delivers and development. Their Model-Aided Drug Invention
1:1 clinical correlation, it can be used to predict response of (MADI) approach employs proprietary algorithms and
an indication to a specific drug (or drug combination), or to software to support groups worldwide in decision-making
better understand MOA of a given compound. from early research through clinical trials.
www.mitrabiotech.com www.appliedbiomath.com
Event Partner Program Partner
Crown Bioscience is a global Personalis, Inc. provides
drug discovery and development genomic solutions to
solutions company providing support the development of
translational platforms to personalized cancer vaccines
advance oncology, inflammation, cardiovascular and and other next-generation cancer immunotherapies.
metabolic disease research. Our patented ACE Technology improves every step in
the sequencing process, from nucleic acid extraction, to
www.crownbio.com sequencing, to data analytics. This delivers augmented
coverage of difficult-to-sequence genomic regions that
are missed with conventional sequencing techniques. This
comprehensive approach provides data of the highest
quality to enable the rational design and development of
effective cancer immunotherapies
www.personalis.com
Exhibitor Exhibitor
Caprion Biosciences is a Immudex manufactures MHC
specialty laboratory CRO with Dextramers, the leading
an established track record in MHC multimer reagent for
biomarkers, bioanalytical and the detection of antigen-
immune monitoring services. Through its advanced specific T cells. Under an agreement with the US Cancer
immune monitoring platform, Caprion supports the Immunotherapy Consortium (CIC) and the European
development of vaccine and immunotherapy programs Cancer Immunotherapy Consortium (CIMT), Immudex
that require the characterization of innate and adaptive also provides MHC Multimer and Elispot proficiency panel
immunity. services worldwide.
www.caprion.com www.immudex.com
Denvor Oorloff
Partnerships Director
GET INVOLVED Tel: +44 (0)203 141 8748
Email: denvor.oorloff@hansonwade.com
Tel: +1 617 455 4188 Mail: info@hansonwade.com
9
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.comICI – IO Combinations Summit
March 19-21, 2019 | Boston
Gain knowledge that will optimize your rationale when
1
READY TO REGISTER? selecting Checkpoint Modulators and Combination
Partners, to find the right combination sooner
Optimize your development process to advance your
3 EASY WAYS TO BOOK 2 combination pipeline
Overcome the key roadblocks that prevent Checkpoint
3 Modulator containing combinations from reaching the
www.ici-io.com/take-part/register market
Team Discounts*
Tel: +1 617 455 4188 • 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Email: info@hansonwade.com Please note that discounts are only valid when three or more
delegates from one company book and pay at the same time.
Contact: register@hansonwade.com
SECURE YOUR PLACE
Solution Provider Pricing Standard Price
Conference + Workshop $3498 (save $100)
Conference Only $2899
Workshops (Each) $699
Drug Developer Pricing Standard Price
Conference + Workshop $2198 (save $100)
Conference Only $1899
Workshops (Each) $399
VENUE
The Colonnade Hotel
120 Huntington Avenue, Boston,
MA 02116, Unites States
For further information or assistance, please visit
www.colonnadehotel.com
TERMS & CONDITIONS
Full payment is due on registration. Cancellation and Substitution Policy: Changes to Conference & Agenda: Hanson Wade reserves the right to Data Protection: The personal information shown and/or provided by you will
Cancellations must be received in writing. If the cancellation is received more postpone or cancel an event, to change the location or alter the advertised be held in a database. It may be used to keep you up to date with developments
than 14 days before the conference attendees will receive a full credit to a speakers. Hanson Wade is not responsible for any loss or damage or costs in your industry. Sometimes your details may be obtained or made available to
future conference. Cancellations received 14 days or less (including the four- incurred as a result of substitution, alteration, postponement or cancellation third parties for marketing purposes. If you do not wish your details to be used
teenth day) prior to the conference will be liable for the full fee. A substitution of an event for any reason and including causes beyond its control including for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6
from the same organization can be made at any time. without limitation, acts of God, natural disasters, sabotage, accident, trade or Honduras Street, London EC1Y 0TH
industrial disputes, terrorism or hostilities.
Tel: +1 617 455 4188 Mail: info@hansonwade.com
10
Immune Checkpoint Inhibitors @ici_checkpoint www.Ici-io.comYou can also read
